ConductScience.org, home

Paper41102420

Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight.

Tanaka M and 1 other. Hypertens Res, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight. Papers, record 41102420. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41102420

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight.
PubMed
Journal
Hypertens Res
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-11-05
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tanaka MMasami
2Itoh HHiroshi

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Glucagon-Like Peptide-1 Receptor AgonistsMajor topic
Blood PressureMajor topic
Body WeightMajor topic
Antihypertensive AgentsMajor topic
Humans
Animals
Diabetes Mellitus, Type 2
Hypertension
Hypoglycemic Agents

Source PubMed

Download CSV of topics

References78

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138832935Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node.Cardiovasc Res2024https://conductscience.org/library/papers/38832935PubMed
225414155Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.Diabetes Care2015https://conductscience.org/library/papers/25414155PubMed
325882864Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients.J Hypertens2015https://conductscience.org/library/papers/25882864PubMed
429985448Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats.Hypertens Res2018https://conductscience.org/library/papers/29985448PubMed
537258623Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?Hypertens Res2023https://conductscience.org/library/papers/37258623PubMed
618758869Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure.Obes Surg2009https://conductscience.org/library/papers/18758869PubMed
727777261Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.Eur J Endocrinol2017https://conductscience.org/library/papers/27777261PubMed
819776173Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.Am J Physiol Renal Physiol2009https://conductscience.org/library/papers/19776173PubMed
934170647Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med2021https://conductscience.org/library/papers/34170647PubMed
1036964557Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.Cardiovasc Diabetol2023https://conductscience.org/library/papers/36964557PubMed
1122320349Investigation of the haemodynamic effects of exenatide in healthy male subjects.Br J Clin Pharmacol2012https://conductscience.org/library/papers/22320349PubMed
1230473097LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.Mol Metab2018https://conductscience.org/library/papers/30473097PubMed
1326803771GLP-1 Agonists and Blood Pressure: A Review of the Evidence.Curr Hypertens Rep2016https://conductscience.org/library/papers/26803771PubMed
1436196465The HOPE Asia network 2022 up-date consensus statement on morning hypertension management.J Clin Hypertens (Greenwich)2022https://conductscience.org/library/papers/36196465PubMed
1523463656Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.J Clin Endocrinol Metab2013https://conductscience.org/library/papers/23463656PubMed
1626910107Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.Diabetes Obes Metab2016https://conductscience.org/library/papers/26910107PubMed
1726956188Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy.Am J Physiol Endocrinol Metab2016https://conductscience.org/library/papers/26956188PubMed
1823653460Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats.Endocrinology2013https://conductscience.org/library/papers/23653460PubMed
1921593184Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.Am J Physiol Renal Physiol2011https://conductscience.org/library/papers/21593184PubMed
2028869249GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.Nat Rev Nephrol2017https://conductscience.org/library/papers/28869249PubMed

See all 78 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42291049Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities.Am J Prev Cardiol2026https://conductscience.org/library/papers/42291049PubMed
42033464Anti-obesity medications in children and adolescents: blood pressure and chronic kidney disease implications.Pediatr Nephrol2026https://conductscience.org/library/papers/42033464PubMed
41878820Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit.Circ Heart Fail2026https://conductscience.org/library/papers/41878820PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AGT183PubTator's text mininghttps://conductscience.org/library/genes/183NCBI Gene
GCG2641PubTator's text mininghttps://conductscience.org/library/genes/2641NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41102420

GET https://conductscience.org/api/papers/v1/41102420/references?page=2